Ollin refuels with $330M to back pivotal tests of Vabysmo challenger
Summary
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a China-based developer — had certain advantages over Roche’s eye treatment.
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For China, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketChina
- ImpactMedium (64/100)
- SignalFunding Research